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University of California, Los Angeles
New generation in vitro high-throughput screening (HTS) assays
for the assessment of engineered nanomaterials provide an opportu-
nity to learn how these particles interact at the cellular level, par-
ticularly in relation to injury pathways. These types of assays are
often characterized by small sample sizes, high measurement error
and high dimensionality, as multiple cytotoxicity outcomes are mea-
sured across an array of doses and durations of exposure. In this
paper we propose a probability model for the toxicity profiling of en-
gineered nanomaterials. A hierarchical structure is used to account
for the multivariate nature of the data by modeling dependence be-
tween outcomes and thereby combining information across cytotox-
icity pathways. In this framework we are able to provide a flexible
surface-response model that provides inference and generalizations of
various classical risk assessment parameters. We discuss applications
of this model to data on eight nanoparticles evaluated in relation to
four cytotoxicity parameters.
1. Introduction. Nanotechnology is rapidly growing and currently used
in various industries such as food, agriculture, electronics, textiles and health
care. The widespread use of engineered nanomaterials (ENM) in over 800
consumer products increases the likelihood that these materials will come
into contact with humans and the environment [Maynard et al. (2006),
Kahru and Dubourguier (2009)]. Many biological processes take place at
the nanoscale level, and the introduction of ENMs into living organisms
could lead to interference in the molecular and cellular processes that are
critical to life [Nel et al. (2009)]. This potential for human and environmen-
tal hazard has spurred recent interest in early identification of potentially
hazardous nanomaterials. Knowledge about the potential hazard of nanoma-
terials is still lacking and a lot of study is required to understand how ENM
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Fig. 1. Fluorescence images and heat map of raw data. On the left are fluorescence
images of RAW cells treated with various nanomaterials (quantum dot, platinum and a
negative control) and dyed with compatible dye combinations including MitoSox, JC1, PI
and Fluo-4. The subsequence fluorescence read-out, measured at varying wavelengths, pro-
vides a measure of the number of cells positive for the response. On the left is a heat map
of the raw data for each particle and outcome. Colder colors indicate a smaller percentage
of cells positive for the response and warmer colors indicate a larger percentage of cells
positive for the response.
properties such as size, shape, agglomeration state, solubility and surface
properties could lead to hazard generation at the nano-bio interface [Stern
and McNeil (2008), Nel et al. (2006)].
Current research in nano-toxicology includes new generation high-through-
put screening (HTS) assays, which enable the simultaneous observation of
multiple cellular injury pathways across an array of doses and times of ex-
posure. In this article, for example, we analyze data on eight metal and
metal oxide nanoparticles, monitored in relation to four cellular injury re-
sponses, derived from the hierarchical oxidative stress model of Nel et al.
(2006) and Xia et al. (2006). All four outcomes are measured contempora-
neously over a grid of ten doses and seven hours of exposure (see Figure 1).
The four measured responses include mitochondrial superoxide formation,
loss of mitochondrial membrane potential, elevated intracellular calcium and
membrane damage [George et al. (2009)]. For increasing dosage and dura-
tion of exposure, we observe typical dose-response kinetics, with outcomes
possibly depending on one another.
These assays provide an opportunity to help define biological relation-
ships and may suggest which nanoparticles are likely to have an in vivo
effect. While HTS assays cannot replace traditional animal studies, they are
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less costly, less labor intensive and can be used to explore the large number
of potential nanomaterial variables that can influence human health hazards
[Meng et al. (2010), Stanley et al. (2008), Maynard et al. (2006)]. The feasi-
bility and utility of HTS assays have been illustrated in various fields such
as functional genomics, with the use of microarray technology, as well as
in pharmacology for the rapid screening of potential drug targets [Hoheisel
(2006), White (2000)]. In toxicology, risk assessment involves the character-
ization of hazard as well as the potential for exposure while accounting for
all assumptions and uncertainties. The HTS framework provides a wealth
of information about cellular injury pathways but proves a challenge for the
classic risk assessment paradigm. In fact, there is still disagreement in the
HTS setting on how to define and how appropriate are classical risk assess-
ment parameters such as no observable adverse effect level (NOAEL), the
lowest observable adverse effect level (LOAEL) and the dose that produces
50% of the maximum response (EC50), among others.
Parametric functions such as families of sigmoidal curves are frequently
used to fit dose-response data. Some commonly used sigmoidal models in-
clude log-logistic models, log-normal models and Weibull models [see Ritz
(2010) for a recent review of these models]. The log-logistic functions are
the most frequently used for modeling dose-response data in toxicology. The
four parameter log-logistic model can be expressed as follows:
f(x; b, c, d, h) = c+
d− c
1 + exp[b{log(x)− log(h)}]
.(1)
Here h, the inflection point in the curve, provides a convenient risk assess-
ment parameter, since it can be interpreted as the 50% effective or inhibitory
dose (EC50, IC50) [Emmens (1940)]. Other special cases of this model in-
clude the 3 parameter log-logistic model which leads to the famous Hill
equation [Hill (1910)] and special cases of the Michaelis–Menton kinetics.
Further extensions of these models include the five parameter log-logistic
function, which provides a bit more flexibility by allowing the function to be
asymmetric [Finney (1979)], and the Brain-Cousens model, which includes
an extra parameter to account for a possible favorable response to a toxin at
low concentrations [Calabrese and Baldwin (2003)]. In general, these models
assume that the dose-response function is completely known apart from the
few parameters to be estimated, usually by determining which values of the
parameters result in the best fit to the dose-response function.
Several other methods have been proposed to model nonlinear dose-response
relationships relaxing strictly parametric assumptions. Ramsay (1988) pro-
posed the use of monotone regression splines to model a dose-response func-
tion. In this case, piecewise polynomials or splines can allow greater flexibil-
ity while achieving monotonicity by imposing constraints on the estimated
function. Li and Hunt (2004) proposed the use of linear B-splines with one
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random interior knot to model a nonlinear dose-response curve. In this con-
text, the random interior knot provides inference on the dose at which the
toxin begins to take effect and thereby provides a useful parameter for risk
assessment. Kong and Eubank (2006) suggested the use of functions that
combine smoothing spline techniques and the nonnegativity properties of
cubic B-splines to estimate the dose-response curve. The use of nonpara-
metric techniques to estimate dose-response curves often provides a more
realistic representation of the data generating process. At the same time,
however, some of these techniques make it more difficult to interpret the
model in terms of classical risk assessment.
Recent literature advocates the simultaneous use of multiple outcomes to
assess risk. Regan and Catalano (1999) proposed a bivariate dose-response
model that accounts for the dependence among outcomes of developmental
toxicity using generalized estimating equations. Geys et al. (2001) proposed a
similar model for risk assessment of developmental toxicity, but approached
the problem using latent variables. Yu and Catalano (2005) suggested a
model for quantitative risk assessment of bivariate continuous measures of
neurotoxicity using percentile regression. These methods are often aimed at
the analysis of one potentially toxic agent as it relates to adverse events or
continuous outcomes observed in association with exposure over a range of
doses. Their direct applicability to the general HTS setting described earlier
is therefore limited.
From a statistical perspective, cellular interrogation data based on high-
throughput platforms can be characterized as multivariate dependent ob-
servations. Each nanoparticle is indeed associated with a multiple set of
cellular outcomes recorded both longitudinally, in relation to different expo-
sure durations, and cross-sectionally, in relation to a dose escalation design.
This particular design structure suggests that valid statistical inference must
account for potentially complex patterns of dependence between different
observations. A reasonable dependence scheme might, for example, assume
data to be dependent within outcome and particle, as well as between out-
comes for the same particle.
In conjunction with considerations related to the joint sampling distribu-
tion of these data structures, appropriate statistical treatment must account
for nonlinearities in the mean response associated with dose and duration
dynamics. While, in principle, one can choose to define a random response
surface in a completely nonparametric fashion, it is important to maintain
a certain degree of interpretability, especially in relation to standard haz-
ard assessment quantities of interest to substantive scientists. In summary,
perhaps reductively, the overall modeling challenge lies in the definition of a
flexible and interpretable probabilistic representation for a family of depen-
dent dose-response random surfaces.
In this paper we propose a hierarchical dose-response model for the anal-
ysis of HTS data from nanotoxicology. Our model builds on earlier work
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[Hastie and Tibshirani (1986), Li and Hunt (2004)], expanding on them to
account for the multivariate nature of the data and to address the estimation
of a series of two-dimensional dose-response surfaces. We provide a flexible
framework for modeling dose and duration response kinetics jointly, while
providing inference on several risk assessment parameters of interest. We
utilize a hierarchical structure to define dependence between outcomes and
thereby borrow strength across injury pathways, providing the basis for a
comprehensive risk assessment paradigm in HTS studies. We account for
outlying observations via a T -distributed error model and describe how to
carry out inference for the model parameters and their functions on the ba-
sis of simulated draws from their posterior distribution. To our knowledge,
we are the first to propose a principled statistical methodology for the joint
analysis of this new generation of in vitro data.
The remainder of the article is organized as follows. In Section 2 we intro-
duce the proposed model. In Section 3 we discuss parameter estimation and
associated inferential details. Section 4 employs the proposed model for the
analysis of 8 metal oxide nanomaterials and describes inference for various
risk assessment parameters of interest. We conclude with a critical discussion
of the limitations and possible extensions of our method in Section 5.
2. Model formulation.
2.1. Model description. In this section we describe a dose-response model
for a general HTS study, where we monitor a multivariate continuous out-
come y, corresponding to J cytotoxicity parameters, in association with
the exposure of a number of cells to I different ENMs. More precisely,
let yijk(d, t) denote a multivariate response corresponding to ENM i (i =
1, . . . , I), cytotoxicity parameter j (j = 1, . . . , J) and replicate k (k = 1, . . . ,K)
at dose d ∈ [0,D] and time t ∈ [0, T ]. In typical applications one observes
y over a discrete set of doses d˜ = (d1, . . . , dm1)
′ and exposure times t˜ =
(t1, . . . ., tm2)
′. However, for clarity of exposition, we simplify our notation
and without loss of generality refer to a general dose d ∈ [0,D] and time
t ∈ [0, T ]. We introduce the following 4-stage hierarchical model.
Stage 1: Sampling model. The observed response of particle i, cytotoxicity
parameter j and replicate k is modeled as
yijk(d, t) =mij(d, t) + εijk(d, t),(2)
where εijk(d, t) ∼ N(0, σ
2
εj/τi). Here mij(d, t) denotes the response surface
for particle i and outcome j. The proposed response surface describes dose
and duration kinetics for all d ∈ [0,D] and t ∈ [0, T ] and is expected to exhibit
a nonlinear dynamic over these domains. The distribution of yijk is modeled
in terms of the error term εijk as a scaled mixture of normal random variables
to account for outlying observations. The error variance is defined in terms of
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the measurement error variance σ2εj , specific to cytotoxicity parameter j, and
on ENM-specific variance inflation parameter τi. If we define the joint distri-
bution of εijk(d, t) and τi as P (εijk(d, t), τi) = P (εijk(d, t) | τi, σεj)P (τi | ν),
choosing εijk(d, t) | τi, σεj ∼ N(0, σ
2
εj/τi) and τi | ν ∼ Gamma(ν/2, ν/2), it
can be shown that the marginal density of εijk(d, t) | σ
2
εj is distributed as
a T (σ2εj , ν) [West (1984)]. Under this framework, we can borrow strength
across all ENMs by assuming the error variance is the same, but retain ro-
bustness in the model by allowing ENM-specific departures from normality.
We allow the measurement error σεj to vary between cytotoxicity parameters
due to heterogeneity in the cytotoxicity outcomes.
Stage 2: Response model at the ENM by cytotoxicity parameter level. The
dose-response surface mij(d, t) spans two dimensions (dose and time), and is
modeled in an additive fashion as described by Hastie and Tibshirani (1986).
If we let (αij ,β
′
ij ,φ
′
ij ,γ
′
ij , ψ
′
ij ,δ
′
ij,χ
′
ij)
′ be a parameter vector indexing the
dose-response surface mij(d, t), we can then define
mij(d, t) = αij + fij(d;φij ,βij) + gij(t;ψij ,γij) + hij(d, t;χij ,δij).(3)
Here fij(d;φij ,βij) is a function modeling the effect of dose d on response
j for ENM i. Similarly, gij(t;ψij ,γij) is the function modeling the effect of
time t and hij(d, t;χij , δij) is the function modeling the interactive effect of
dose and time. More specifically, we model the interaction of dose and time
in a semi-parametric fashion as hij(dt;χij ,δij). This parameterization allows
us to retain direct interpretation of the model parameters, while avoiding
over-fitting of sparse data. To ensure likelihood identifiability, we require,
without loss of generality, that fij(d= 0;φij,βij) = 0, gij(t= 0;ψij ,γij) = 0,
and hij(dt= 0;χij,δij) = 0. The parameters αij can therefore be interpreted
as the background response level for each particle and outcome.
We model dose-response curves fij(d;φij,βij), duration-response curves
gij(t;ψij,γij) and dose-time response curves hij(dt;χij ,δij) as linear com-
binations of basis functions. Specifically, we use linear B-splines with two
random interior knots as points where the slope changes in a piecewise lin-
ear fashion. Let B(x,η) denote a 4-dimensional B-spline basis with inte-
rior knots η = (η1, η2)
′. Also, let βij = (βij1, . . . , βij4)
′, γij = (γij1, . . . , γij4)
′
and δij = (δij1, . . . , δij4)
′ be 4-dimensional vectors of spline coefficients. The
functions fij(d;φij ,βij), gij(t;ψij ,γij) and hij(dt;χij ,δij) can then be rep-
resented as follows:
fij(d;φij,βij) = B(d,φij)
′βij,
gij(t;ψij,γij) = B(t,ψij)
′γij ,(4)
hij(dt;χij ,δij) = B(dt,χij)
′δij .
Identifiability restrictions fij(d= 0;φij,βij) = 0, gij(t= 0;ψij,γij) = 0 and
hij(dt = 0;χij,δij) = 0 are implemented by fixing βij1 = 0, γij1 = 0 and
δij1 = 0, for all particles and outcomes (see Figure 2 for an illustration).
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Fig. 2. Dose-response as a change-point model. (left) B-spline basis function of degree 1,
corresponding to change points (interior knots) at log doses of 1.5 and 4.5. (Middle) Ex-
ample dose-response curve. The basis function on the left corresponds to a spline function
with 2 change points. Each random change point has a corresponding distribution, result-
ing in a smooth dose-response curve. (Right) Example of a marginal prior distribution on
the change points corresponding to the dose-response curve on the left. This formulation
favors (a priori) the choice of conservative values for the location of the first change point
(solid line), and a relatively diffuse prior for our second change point (dotted line).
Modeling dose and duration-response curves as piecewise linear functions
allows for considerable flexibility while maintaining direct interpretability of
the model parameters. Recall that in our formulation the interior knots are
estimated as random quantities. This allows, marginally, for a smooth dose-
response trajectory that is automatically adjusted to fit the data. The main
advantage of the proposed functional representation is that, in the absence
of a dose-time interaction, one can interpret the first interior knot φij1 as the
dose at which ENM i becomes toxic in relation to cytotoxicity parameter
j (Maximal Safe Dose—similar to the classical NOAEL concept). A similar
interpretation can be given to ψij1, in relation to duration-response. Note
that the foregoing interpretation is contingent on fixing βij2 = 0, γij2 = 0 and
χij2 = 0 when assuming no effect before the first change-point, and βij2 ≤ 0,
γij2 ≤ 0 and χij2 ≤ 0 when assuming a tonic effect before the first change
point. In the presence of a dose-time interaction, interpretation changes
slightly and we instead consider the idea of safe exposure regions, which
represent doses and time exposure combinations that do not induce cyto-
toxicity. Finally, in the absence of an interaction, the parameters φij2 and
ψij2 are respectively interpreted as the dose and time at which the response
stabilizes, or cells start a possible recovery process.
We can expand the model further to allow for the exclusion of interaction
functions where not needed. To do that, we include a latent indicator variable
ρij , so that for each particle i and outcome j
mij(d, t) =


αij + fij(d;φij,βij) + gij(t;ψij ,γij), if ρij = 0,
αij + fij(d;φij,βij) + gij(t;ψij ,γij) + hij(dt;χij,δij),
if ρij = 1,
(5)
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where ρij ∼ Bern(π) and π ∼ U(0,1). We require that if ρij = 0, hij(dt;χij ,
δij)> 0, to ensure identifiability. The indicator variable ρij can then be used
to test explicitly for the dose-time interactions. The exchangeable Bernoulli
trials prior on ρij is designed to account for multiplicities [Scott and Berger
(2006)]. This trans-dimensional parameterization is key to avoid overfitting,
to facilitate parameter interpretation, and to allow for testing of specific
scientific hypotheses related to the biological interference of nanomaterials.
For each ENM i and response j, we define the following prior distributions
for αij , βij , γij , and δij :
αij ∼N(αoi , σ
2
αi),
βij ∼N4(βoi ,Σβi)I{βij1 = 0;βij2 ≤ 0; (βij3, βij4)≥ 0},(6)
γij ∼N4(γoi ,Σγi)I{γij1 = 0;γij2 ≤ 0; (γij3, γij4)≥ 0},
δij | ρij = 1∼N4(mδij ,vδij )I{δij1 = 0; δij2 ≤ 0; (δij3, δij4)> 0}.
The truncated support for βij , γij and δij imposes functional constraints
on f(·), g(·) and h(·), which are consistent with the expected behavior of
canonical dose and duration kinetics. At the same time, however, it allows
for the system to recover by permitting a decreasing slope after the second
change point. The covariance matrix Σβi has diagonal elements σβiℓ , ℓ=
1, . . . ,4, and off diagonal elements equal to 0; similarly for Σγi .
Prior distributions for φij , ψij and χij are defined to satisfy the following
constraints: (0 < φij1 < φij2 < D), (0 < ψij1 < ψij2 < T ) and (0 < χij1 <
χij2 < DT ). More precisely, we assume that the joint distribution of the
interior dose and duration knots follows a generalized bivariate Beta density
function, so that
φij ∼B2(aφ1 , bφ1 , aφ2 , bφ2 ,D),
ψij ∼B2(aψ1 , bψ1 , aψ2 , bψ2 , T ),(7)
χij ∼B2(aχ1 , bχ1 , aχ2 , bχ2 ,DT ).
Here we assume that a random vector x= (x1, x2)
′ is distributed according to
a generalized bivariate Beta distribution function (x∼B2(a1, b1, a2, b2,m)),
with support S(x) = {(x1, x2) : 0< x1 < x2 <m} if and only if
p(x | a1, b1, a2, b2,m)
= p(x1 | a1, b1,m)p(x2 | x1, a2, b2,m)(8)
=
1
B(a1, b1)
xa1−11 (m− x1)
b1−1
ma1+b1−1
1
B(a2, b2)
(x2 − x1)
a2−1(m− x2)
b2−1
(m− x1)a2+b2−1
.
The foregoing formulation can be seen as a generalization of the Dirichlet
distribution over a two-dimensional simplex. This general formulation can be
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simplified further, in order to achieve a right-skewed marginal distribution
for x1 and a uniform conditional distribution for x2 given x1. This is achieved
by assuming b1 > a1 > 1 and a2 = b2 = 1.
Making use of this construction, we simplify the prior distribution in (7)
as follows:
φij ∼B2(1, λφi1 , λφi2 ,1,1,D)I{λφi2 > λφi1 > 1},
ψij ∼B2(1, λψi1 , λψi2 ,1,1, T )I{λψi2 >λψi1 > 1},(9)
χij ∼B2(1, lχi1 , lχi2 ,1,1, T )I{lχi2 > lχi1 > 1}.
From a regulatory standpoint, this formulation favors (a priori) the choice of
conservative values for the location of the first change point and a relatively
diffuse prior distribution for our second change point (see Figure 2).
Stage 3: Response model at the ENM level. For each ENM i, we exploit
conditional conjugacy to define the following prior distributions for popula-
tion level parameters:
αoi ∼N(mαi , vαi), βoi ∼N4(mβi ,vβi), γoi ∼N4(mγi ,vγi).(10)
In the absence of an interaction, the parameters βoi and γoi represent sum-
maries of the dose and duration-response trajectories across all outcomes
and the αoi parameters represent a summary of the baseline response across
all outcomes. In the presence of an interaction, we may construct these sum-
maries conditionally on specific doses and durations of exposure.
Finally, considering the distribution introduced in (9), we define a prior
model for population level parameters λφi = (λφi1 , λφi2) and λψi = (λψi1 , λψi2)
as follows:
λφiℓ ∼Gamma(aλφiℓ , bλφiℓ), λψiℓ ∼Gamma(aλψiℓ , bλψiℓ),(11)
where ℓ= 1,2. The parameters λφi and λψi can be used to construct sum-
maries of dose and duration-response change points across all outcomes.
Shape hyperparameters (aλφiℓ , bλφiℓ) and (aλψiℓ , bλψiℓ) can be tuned to favor
more or less conservative values for the change-point locations at the particle
level.
Stage 4: Hyperpriors. We complete the model by specifying prior distri-
butions on our hyperparameters as follows:
1/σ2εj ∼Gamma(aεj , bεj), 1/σ
2
αi ∼Gamma(aαi , bαi),
(12)
1/σ2βi ∼Gamma(aβi , bβi), 1/σ
2
γi ∼Gamma(aγi , bγi).
We model our precision parameters as gamma distributions, exploiting con-
ditional conjugacy. Again, prior parameters can be tuned to define more
or less informative distributions consistent with the scale of the outcomes
[Gelman (2006)]. Note that in our formulation, x∼Gamma(a, b) denotes a
Gamma distributed random quantity with shape a and rate b, such that
E(x) = a/b.
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3. Estimation and inference.
3.1. Posterior simulation via MCMC. Using the B-spline representation
introduced in Section 2.1, we can write the expected jth response level
associated with ENM i, at dose d and exposure time t as
mij(d, t;αij ,βij, . . .) =


αij +B(d,φij)
′βij +B(t,ψij)
′γij , if ρij = 0,
αij +B(d,φij)
′βij +B(t,ψij)
′γij +B(dt,χij)
′δij ,
if ρij = 1.
Let β = {βij : i = 1, . . . , I, j = 1, . . . , J} and define γ and δ in a similar
fashion. These parameters denote the full set of spline coefficients. Further-
more, consider knot parameters φ= {φij : i= 1, . . . , I, j = 1, . . . , J}, with ψ
and χ similarly defined, and background response parameters α= {αij : i=
1, . . . , I, j = 1, . . . , J}. Finally, let σ2ε = (σ
2
ε1 , . . . , σ
2
εJ )
′ and τ = (τ1, . . . , τI)
′. If
we denote with Y the complete set of response values for all particles and
cytotoxicity outcomes, the likelihood function can be written as follows:
L(β,γ,δ,φ,ψ,χ,α,σ2ε,τ ,ρ |Y)
(13)
∝
∏
i,j,k,d,t
[(
σ2εj
τi
)−1/2
exp
{
−
(yijk(d, t)−mij(d, t; . . .))
2
2σ2εj/τi
}]
,
where the product is taken over all replicates k, particles i, outcomes j,
doses d and times t. We are interested in the posterior distribution
P (β,γ,δ,φ,ψ,χ,α,σ2ε,τ ,ρ |Y)∝ L(β,γ,δ,φ,ψ,χ,α,σ
2
ε,τ ,ρ |Y)
(14)
× P (β,γ,δ,φ,ψ,χ,α,σ2ε,τ ,ρ),
where the prior model P (β,γ,δ,φ,ψ,χ,α,σ2ε,τ ,ρ) is fully described in
Section 2.1. This quantity is, however, unavailable in closed analytic form,
therefore, we base our inference on Markov Chain Monte Carlo (MCMC)
simulations.
The proposed posterior simulation algorithm combines Gibbs steps within
Metropolis–Hastings steps in a hybrid sampler, where we update parame-
ters component-wise [Tierney (1994)]. We directly sample components when
closed-form full conditional distributions are available using a Gibbs sam-
pling algorithm [Geman and Geman (1984), Gelfand and Smith (1990)];
otherwise, we use the Metropolis–Hastings (MH) approach [Metropolis et
al. (1953)]. Available full conditional distributions are given in the supple-
mental article, Appendix A [Patel et al. (2012)]. As we are considering se-
lection of interaction functions in a trans-dimensional setting, we implement
a reversible jumps algorithm to move between models with and without the
dose-time interaction function hij(dt;χij ,δij) [Green (1995)]. The model in-
dicator ρij and corresponding model parameters δij and χij are updated
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jointly using reversible jump MCMC steps. After the model structure has
been specified, the model parameters are updated from their corresponding
conditional posterior distributions. The proposed sampling scheme can be
summarized as follows.
1. Fixed dimensional updates. Given the current state of the latent in-
teraction indicators ρij , response surfaces are uniquely defined as in (5).
Posterior sampling is standard here and proceeds by updating spline co-
efficients β,γ and δ from their conditional posterior via direct simulation
[Patel et al. (2012)]. Knot parameters φ,ψ and χ are updated via a MH
step. For example, when sampling the interior knot parameters φ we use
an appropriate proposal kernel q(φ0ijℓ, φ
1
ijℓ) to efficiently construct Markov
chains with the desired stationary distribution. While accounting for the
fact that φij1 < φij2, we consider uniform proposal densities of the form
q(φ1ijℓ | φ
0
ijℓ) =U(φ
0
ijℓ−wφijℓ, φ
0
ijℓ+wφijℓ)I(Sφ),(15)
where ℓ= 1,2. Here Sφ denotes the appropriate support and must satisfy the
constraints 0 < φij1 < φij2 < D. Proposed values of φijℓ are accepted with
the following probabilities:
min
{
1;
p(φ1ijℓ | yijk,θ\φ)
p(φ0ijℓ | yijk,θ\φ)
q(φ0ijℓ | φ
1
ijℓ)
q(φ1ijℓ | φ
0
ijℓ)
}
, ℓ= 1,2.(16)
To tune proposal kernels, each φijℓ was sampled using an initial value of w
that was re-calibrated throughout the burn-in period to achieve an accep-
tance rate between 30% and 70% [Roberts and Rosenthal (2001)]. Specifi-
cally, the acceptance rate of φijℓ was monitored every 200 iterations through-
out the burn-in period with wφijℓ adjusted appropriately if the acceptance
rate did not fall within the desired range. A similar Metropolis–Hastings
scheme was adapted for sampling the duration-response parameters ψ, dose-
time interaction parameters χij | ρij = 1, as well as for population level knot
parameters.
2. Trans-dimensional updates. We sample the model space by randomly
proposing the birth or death of dose-time interaction functions hij(·). This
is accomplished by selecting a particle i and outcome j at random and by
jointly updating ρij , δij and χij . In detail,
(1) For uniformly random i ∈ (1, . . . , I) and j ∈ (1, . . . , J), propose a sys-
tematic change ρ0ij → ρ
1
ij = 1− ρ
0
ij . We assume for the moment that we pro-
pose moving from ρ0ij = 0 to ρ
1
ij = 1, implying the birth of a new interaction
function hij(·).
(2) Propose new knots and spline coefficients δ1ij ∼ q(δ
1
ij) and χ
1
ij ∼
q(χ1ij).
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Table 1
Risk assessment parameters. ENM level risk assessment parameters associated with the
hierarchical model introduced in 2.1. For each parameter we summarize its function in
the model and the related interpretation as a cytotoxicity risk factor
Parameter Model function Parameter interpretation
β∗3ij Dose-response slope from φij1 to φij2 Overall dose effect
γ∗3ij Duration-response slope from φij1 to φij2 Overall exposure time effect
φ1ij Dose-response change point 1 Maximal safe dose
ψ1ij Duration-response change point 1 Maximal safe exposure time
m∗ij Evaluated numerically Maximal response
(3) Accept the proposed move with probability τb =min(1,Rb), where
Rb =
p(yijk | δ
1
ij,χ
1
ij , ρ
1
ij,θ\δij ,χij ,ρij )
p(yijk | ρ
0
ij ,θ\δij ,χij ,ρij)
p(δ1ij | ρ
1
ij)p(χ
1
ij | ρ
1
ij)
q(δ1ij)q(χ
1
ij)
p(ρ1ij)
p(ρ0ij)
,(17)
where we use θ\ω to denote all model parameters, with the exception of ω.
In the case where the proposed move would imply a death of an interaction
function (ρ0ij = 1→ ρ
1
ij = 0), the acceptance probability would simply be
τd = 1/τb.
While the proposal densities q(δij) q(χij) in (17) can in theory be defined
almost arbitrarily, to guarantee efficient exploration of the model space, we
consider truncated multivariate normal proposals for δij and χij centered
around regions of high posterior probability. Efficient optimization within
the MCMC iterations is achieved using standard profile likelihood ideas
[Severini and Staniswalis (1994)].
3.2. Posterior inference. In this section we discuss inference on ENM-
specific risk assessment parameters, based on draws from the posterior dis-
tribution described in Section 3.1. Table 1 summarizes several quantities of
interest including the maximal safe dose, maximal safe exposure time and
the maximal response. This list is not exhaustive. However, other risk assess-
ment parameters of interest, such as benchmark doses (BMD) or effective
concentrations (ECα), are easily obtained from our model output in a nu-
merical fashion. In the case of a dose-time interaction, these quantities are
defined conditionally on specific doses and durations of exposure.
Let φ
(n)
ij , ψ
(n)
ij , χ
(n)
ij , β
(n)
ij , γ
(n)
ij , δ
(n)
ij , α
(n)
ij and ρ
(n)
ij , n = 1, . . . ,N , de-
note N MCMC draws from the posterior distribution of φij , ψij , χij , βij ,
γij , αij and ρij . In the absence of an interaction term, posterior samples
φ
(n)
ij1 and ψ
(n)
ij1 directly provide us with an approximation of the posterior
distribution for the maximal safe dose and maximal safe exposure time.
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We can also obtain the posterior samples for the overall dose effect, β
∗(n)
ij3 =
β
(n)
ij3 /(φ
(n)
ij2 −φ
(n)
ij1), which is the slope of the dose-response curve between φij1
and φij2. Similarly, we can obtain the posterior distribution for the overall
time effect using posterior samples γ
∗(n)
ij3 = γ
(n)
ij3 /(ψ
(n)
ij2 − ψ
(n)
ij1 ). In the pres-
ence of a dose-time interaction, we can define any of the summaries described
above conditionally on a given dose and time. For example, the maximal safe
dose conditional on exposure time can be defined as min{φij1, χij1/t}, and
posterior samples can be obtained from min{φ
(n)
ij1 , χ
(n)
ij1/t}. Given posterior
draws, one can proceed with the straightforward construction of standard
posterior summaries, such as means, maxima a posteriori, modes, quantiles
and credible regions. We may also be interested in testing for a dose-time
interaction. The expected inclusion probability of the dose-time interaction
function can be estimated using posterior draws ρ
(n)
ij as pˆij =
∑
n ρ
(n)
ij /N .
Given the prior distribution described in (5), this posterior probability is
known to adjust for multiplicities and can be used to test for a dose-time
interaction. Scott and Berger (2006), for example, recommend selecting the
median model, that is, including all interactions for which pˆij > 0.5. Also of
interest is an estimate of the dose-response surface, mij(d, t), for particle i
and outcome j. This surface is, of course, defined in an infinite-dimensional
space. However, given the basis-function representation introduced in Sec-
tion 2.1, we only need finite draws from the parameter set of interest. More
precisely, draws from the marginal posterior distribution of the dose-response
surface for any dose d ∈ [0,D] and time t ∈ [0, T ] are given by
m
(n)
ij (d, t) =


α
(n)
ij +B(d,φ
(n)
ij )
′
β
(n)
ij + B(t,ψ
(n)
ij )
′
γ
(n)
ij , if ρ
(n)
ij = 0,
α
(n)
ij +B(d,φ
(n)
ij )
′
β
(n)
ij + B(t,ψ
(n)
ij )
′
γ
(n)
ij +B(dt,χ
(n)
ij )
′
δ
(n)
ij ,
if ρ
(n)
ij = 1.
(18)
For each φ
(n)
ij , ψ
(n)
ij , β
(n)
ij , φ
(n)
ij and α
(n)
ij , n= 1, . . . ,N , we evaluate the dose-
response function given in (18) over a grid of values D˜ = (d1, . . . , dn)
′ and
T˜ = (t1, . . . , tn)
′. The posterior mean of the samples m
(n)
ij , n = 1, . . . ,N ,
at each value of D˜ and T˜ can be used to summarize the fit of the dose-
response surface, as shown in Figures 3 to 4. Other quantities of interest in-
clude the posterior distribution of the dose-response function fij(d;φij,βij),
duration-response function gij(t;ψij ,γij) and dose-time interaction function
hij(dt;χij ,δij). Draws from the marginal posterior distribution of these func-
tions for any dose d ∈ [0,D] and time t ∈ [0, T ] are given by
f
(n)
ij (d;φij ,βij) = B(d,φ
(n)
ij )
′
β
(n)
ij ,
g
(n)
ij (t;ψij ,γij) = B(t,ψ
(n)
ij )
′
γ
(n)
ij ,(19)
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Fig. 3. Fitted response curves for the quantum dot (QD) ENM. (left) Fitted response sur-
faces (column 1), dose-response function, fij(d) (column 2), duration-response function,
gij(t) (column 3), dose/duration interaction function, hij(dt) (column 4) and associated
95% posterior intervals. In (column 1), the color red represents response values corre-
sponding to lower time points and the color black represents response values corresponding
to higher time points.
h
(n)
ij (dt;χij,δij) = B(dt,χ
(n)
ij )
′
δ
(n)
ij .
For each draw, we evaluate the dose-response functions over a grid of values
d ∈ D˜ and the duration-response functions over a grid of values t ∈ T˜ . As
described before, standard pointwise posterior summaries can be obtained in
a straightforward fashion. Simultaneous confidence bands for the functional
effect of interest can be constructed following the Monte Carlo approxima-
tion suggested by Baladandayuthapani, Mallick and Carroll (2005).
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Fig. 4. Fitted response curves for the gold (Au) ENM. Fitted response surfaces (col-
umn 1), dose-response function, fij(d) (column 2), duration-response function, gij(t) (col-
umn 3), dose/duration interaction function, hij(dt) (column 4) and associated 95% pos-
terior intervals. In (column 1), the color red represents response values corresponding to
lower time points and the color black represents response values corresponding to higher
time points.
Additional summaries of interest can be obtained in a numerical fashion.
For example, the posterior distribution for the maximal response valuem∗ij =
max{mij(d, t);d ∈ [0,D], t ∈ [0, T ]}, may be obtained evaluating m
(n)
ij (d, t)
over a fine grid of doses D˜ and times T˜ . An approximate posterior draw from
m∗ij can be defined as m
∗(n)
ij =max{m
(n)
ij (d, t);d ∈ D˜, t ∈ T˜}. Given smooth-
ness constraints on mij(d, t), defined in Section 2.1, the foregoing procedure
is likely to provide a good approximation to the posterior distribution of
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the maximal response value, provided D˜ and T˜ define a sufficiently detailed
evaluation grid. Similar procedures may be adopted to obtain inference on
other risk assessment parameters like ECαs or BMDs.
4. Applications.
4.1. Synthetic data. To assess estimation of the model presented in Sec-
tion 2, we present a simulation study in the supplemental article, Appendix
B [Patel et al. (2012)]. The dose and time kinetics were simulated in an
additive fashion, from various parametric functions, including both canoni-
cal and noncanonical profiles that are still reasonably interpretable under a
toxicity framework. We also placed increasingly conservative priors on the
population level parameters λφi and λφi in order to assess the sensitivity
of the model results to our choice of prior parameters. In the supplemental
article, Appendix C, we provide an additional sensitivity analysis assessing
model results to our choice of prior model for the change-point parameters
[Patel et al. (2012)]. We compare our prior model results to both a truncated
normal prior and a parameterization of the bivariate beta prior that results
in a uniform prior on the simplex.
Simulation results indicate that our model is robust to model misspec-
ification and is not very sensitive to our choice of prior. We do, however,
maintain that using the bivariate beta prior defined in (8) is likely to be
more appropriate in data analytic frameworks, as the implied stochastic
behavior of the response surface, a priori, reflects more closely the usual bi-
ological mechanisms of toxicity. More specifically, it assigns zero probability
of toxicity to zero dose and time, where toxicity is indeed not expected to
occur. Furthermore, this prior accounts for issues such as dosimetry, in which
the administered doses are confounded by different particle bioavailability.
Therefore, in some particles toxicity is not expected to occur for doses and
times greater than zero.
4.2. Case study background. We illustrate the proposed methodology by
analyzing data on macrophage cells (RAW cells) exposed to eight different
metal and metal-oxide nanoparticles, monitored in relation to four cytotoxi-
city parameters. All four outcomes are measured over a grid of ten doses and
seven times (hours) of exposure (see Figures 3 to 4). Cytotoxicity screening is
based on the hierarchical oxidative stress model [George et al. (2009)]. More
specifically, a multi-parametric assay that utilizes four compatible dye com-
binations and the subsequent change in fluorescence read-outs was used to
measure four responses relating to the highest tier of oxidative stress (toxic
oxidative stress). The four measured responses include mitochondrial super-
oxide formation (MSF), loss of mitochondrial membrane potential (MMP),
elevated intracellular calcium (EIC) and cellular membrane damage (CMD).
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Figure 1 provides fluorescence images of cells exposed to various nanoma-
terials (50 µg/ml and 3 hours), including quantum dot, platinum and a
negative control consisting of no nanomaterials. Row 1 includes images of
cells treated with a dye combination including MitoSox, which permeates
the mitochondria and fluoresces red when oxidized by superoxide. Red flu-
orescence measured in cells treated with MitoSox is therefore a measure of
mitochondrial superoxide formation. Similarly, in Row 2 cells are treated
with a dye combination including JC1, which stains the cytoplasm red in
healthy cells, but forms a monomer in cells with decreased membrane po-
tential and consequently stains the cytoplasm green. Finally, in Row 3 cells
are strained with a dye combination including Fluo-4 and Propidium Iodide
(PI). In cells with damaged membranes, PI is able to permeate the cell and
bind to DNA where it causes the nucleus to emit a red florescence. Fluo-4 is
a dye that emits a green fluorescence in the cytoplasm in cells with elevated
intracellular calcium. Each sample was also stained with a Hoechst dye which
causes all cell nuclei to emit a blue florescence, allowing for a count of the
total number of cells. An analysis of the fluorescence readout, monitored at
varying wavelengths, results in a measure of the percentage of cells positive
for each response. Figure 1 also provides a heat map of the raw responses
for each particle and outcome, where colder colors (blues and greens) in-
dicate a smaller percentages of cells positive for the response and warmer
colors (oranges and reds) indicate a higher percentage of cells positive for
the response. The final data was normalized using a logit transformation to
unconstrain the support so that it can take on values between −∞ and ∞.
Our inferences are based on 20,000 MCMC samples from the posterior distri-
bution in (14), after discarding a conservative 60,000 iterations for burn-in.
MCMC sampling was performed in R version 2.10.0, and convergence diag-
nostics were performed using the package CODA (Convergence Diagnostics
and Output Analysis), [Plummerm et al. (2006)].
4.3. Case study analysis and results. We fit the model described in Sec-
tion 2.1 to the metal-oxide data set described in the previous section. The
prior on the interior knot parameters was modeled using the simplified den-
sity described in (9). A set of relatively noninformative Gamma(2,1) and
Gamma(3,1) priors were considered for the components of both λφi and
λψi , along with a vague B2(2,3,1,1,DT ) prior for our dose-time interaction
change-point parameter χij . We also fixed βij2 = 0 and γij2 = 0, assuming no
effect before φij1 and ψij1, thereby allowing, in the absence of a dose-time in-
teraction, the interpretation of φij1 as the maximal safe dose and ψij1 as the
maximal safe exposure time. Similarly, when ρij = 1, we fixed δij2 = 0. We
placed Gamma(0.01,0.01) priors on the 1/σεj parameters, Gamma(1,0.1)
priors on all remaining precision parameters and N(0,10) priors on the αoi
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Fig. 5. Graphical model diagnostics. (Bottom) Probability Integral Transform assessing
empirical calibration of the posterior predictive distribution. (Top) Mean and 95% posterior
intervals of the posterior predictive mean response across all doses and times of exposure,
for all outcomes and particles 1 through 8 (QD, ZnO, Fe3O4, Pt, Ag, SiO2, Al2O3, Au).
Also included are the empirical mean responses across all doses and times of exposure
(red).
parameters. The parameters βoi and γoi are modeled as truncated multivari-
ate normals with mean 1 and a covariance matrix with diagonal elements
10 and off-diagonal elements 0. Finally, we placed a prior distribution on
the degrees of freedom parameter ν, for the T -distributed error described
in Section 2.1. We specified the prior to be uniform on 1, 2, 4, 8, 16 and
32 degrees of freedom [Besag and Higdon (1999)]. In concordance with our
synthetic data experiments, a sensitivity analysis on the case study data set
proved robust to reasonable variations in the prior specification.
We provide graphical summaries of goodness of fit and posterior predic-
tive performance in Figure 5. The top panel shows the mean and 95% poste-
rior intervals of the posterior predictive mean response across all doses and
times of exposure (black), along with the empirical mean response (red), for
each particle and outcome. In all cases the empirical mean response is con-
tained within the 95% posterior intervals of the posterior predictive mean
distribution, indicating good average posterior coverage across doses and
times of exposure. The bottom panel provides a plot of the probability in-
tegral transform histogram for the entire model [Gneiting, Balabdaoui and
Raftery (2007)]. Visual assessment of the plot indicates that it is close to
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Fig. 6. Safe exposure regions for the quantum dot (QD) and platinum (Pt) nanomate-
rials. For each particle and outcome we can define dose and time exposure regions which
do not induce cytotoxicity. Red colored regions indicate greater cytotoxicity to the cells,
whereas blue colored regions indicate reduced risk. Contour lines quantitate the median es-
timated response, relative to the background, where zero response areas can be interpreted
as safe exposure regions.
uniformity, suggesting relatively good posterior predictive calibration. Ad-
ditional summaries and diagnostic tools are detailed in the supplemental
article, Appendix E [Patel et al. (2012)].
Figures 3 and 4 illustrate data and results associated with two of the
particles examined in this HTS study. Particularly, we report inference for
platinum and quantum dot nanomaterials for each of the 4 cytotoxicity
outcomes. Inference for the remaining 6 particles is reported in the sup-
plemental article, Appendix D [Patel et al. (2012)]. In these two figures,
column 1 shows expected posterior dose-response surfaces across dose and
time for all outcomes. As the posterior expectation marginalizes over the
interior knots, smooth surfaces reflect the uncertainty about the location of
these change points and provide an illustration of how the proposed tech-
nique will adjust for smoothness in an unsupervised fashion. Also included
are functional posterior expectations associated with dose-response curves
fij(d) (column 2), which represent the effect due to dose, duration response
curves gij(t) (column 3), which represent the effect due to exposure time,
and the expected dose-time interaction function hij(t) (column 4).
Figure 6 provides a plot of the estimated median response, relative to
the background, for different doses and times of exposure. Blue colors in-
dicate safety regions or areas of reduced risk to the cells, while red colored
regions indicate increased risk of cytotoxicity. Finally, Figure 7 provides pos-
terior summary estimates including mean and 95% posterior intervals for the
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Fig. 7. Maximal Safe Dose for the quantum dot (QD) and platinum (Pt) nanomaterials.
Posterior summary estimates of the maximal safe dose, conditional on exposure time,
including the posterior mean and associated 95% posterior intervals. In the case of no
interaction, the maximal safe dose is the same across all times.
maximal safe dose, conditional on the duration of exposure. Note that in the
absence of a dose-time interaction, the maximal safe dose is the same across
all exposure times.
Quantum dot (QD) shows a relatively high toxic response for plasma
membrane damage and mitochondrial superoxide formation. In particular,
we see a more pronounced dose effect for membrane damage and both a
time, dose and significant dose-time interaction (ρˆ = 0.99) effect for mito-
chondrial superoxide formation. This supports what has previously been
demonstrated in conventional assays that QD nanoparticles stabilized by
toluene are capable of inducing tiers 2 and 3 oxidative stress responses in-
duced by the toluene [George et al. (2011)]. Platinum (Pt) shows a high
dose and time response for mitochondrial superoxide formation, including
a significant dose-time interaction effect (ρˆ= 0.99), and a pronounced time
effect for elevated calcium but not for mitochondrial depolarization or mem-
brane damage, indicating that the particle induced sublethal effects to the
cell without cytotoxicity. The Zinc oxide nanoparticle (ZnO), reported in the
supplemental article, Appendix D, shows a relatively high toxic response for
plasma membrane damage, elevated calcium and mitochondrial depolariza-
tion [Patel et al. (2012)]. In particular, we see a more pronounced time effect
for the elevated calcium and both a time and dose-response for membrane
damage and mitochondrial depolarization. This again verifies what has pre-
viously been demonstrated in conventional assays, since ZnO nanoparticles
are capable of inducing tiers 2 and 3 oxidative stress responses through Zn+2
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release [George et al. (2009)]. In contrast, the gold nanoparticle (Al), also
reported in the supplemental article, Appendix D, shows very little response
for all outcomes, indicating that, compared to the other particles, it has small
risk of inducing a sublethal or lethal cytotoxic response [Patel et al. (2012)].
5. Discussion. In this article we propose a statistical framework for mod-
eling dependent dose-response surfaces over multivariate outcomes. The pro-
posed methodology accounts for dose and duration kinetics jointly using a
flexible model which does not compromise interpretability. We account for
the multivariate nature of the data using the hierarchical framework and
thereby efficiently combine information and borrow strength across cellular
injury patterns. We account for the nonrobust nature of the data by allowing
for particle specific variance inflation, resulting in a T -distributed model for
the error structure.
The main challenge associated with the class of models proposed in this
manuscript is finding the right balance between model complexity and model
interpretability. An alternative formulation of the dose-response surface would
seek inference for a general smooth surface mij(d, t). However, our simplified
approach, based on the assumptions of additivity and linearity, maintains a
very appealing level of interpretability, allowing for the definition of specific
risk assessment parameters while maintaining an adequate level of flexibility.
A related generalization of the proposed additive framework would include
a more general class of functional interactions to account for a possible syn-
ergistic effect between dose and duration of exposure. This would come at
the cost of reduced interpretability, but, at the same time, could be of clear
scientific interest in some contexts. In this initial modeling effort, we choose
to work with a T -distributed error structure and therefore normalize our re-
sponse to unconstrain the support so that it can take on values between −∞
and∞. An alternative formulation could retain the original scale of the data,
but rather define a generalized multivariate model such that the outcome
distribution can be described using binomial or beta random quantities. This
extension would require a substantial increase in computational complexity,
with the possible need to consider numerical or analytical approximations,
but it is clearly worthy of further methodological exploration.
The hierarchical formulation introduced in this article is easily adapted to
the case where multiple cell lines are used to test for cytotoxicity. A natural
integration strategy would perhaps find motivation in the meta analytic
framework, with information shared between experiments via the structuring
of one extra level in the hierarchy.
Finally, the proposed model can also be expanded by the inclusion of
covariates. This is naturally defined as an extension to stage 3 of the model
introduced in Section 2. The addition of covariates is especially important for
relating specific ENM properties to toxicity, and is therefore an important
area for future work.
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SUPPLEMENTARY MATERIAL
Supplementary Appendices (DOI: 10.1214/12-AOAS563SUPP; .pdf). Full
conditional distributions for the model described in Section 2 are provided
in the supplemental article, Appendix A. Spline coefficients β,γ and δ are
directly sampled from their conditional posterior distributions via direct
simulation (Gibbs step). To assess estimation of the model presented in
Section 2, we present a simulation study in the supplemental article, Ap-
pendix B. The dose and time kinetics were simulated from various paramet-
ric functions. Both canonical and noncanonical profiles that are reasonably
interpretable under a toxicity framework were generated. In addition, we
assess sensitivity of the model results to our choice of prior parameters for
population level interior knot parameters λφi and λφi . In the supplemental
article, Appendix C, we provide an additional sensitivity analysis assessing
model results to our choice of prior model for the change-point parameters.
Alternative prior models assessed include a truncated normal prior and a
parameterization of the bivariate beta prior that results in a uniform prior
on the simplex. The supplemental article, Appendix D, presents results as-
sociated with inference on the 6 remaining particles not presented in Sec-
tion 4.3. Finally, Appendix E discusses model assessment and goodness-of-fit
diagnostics associated with the model described in Section 2.
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